The public float for CHRO is 1.04M, and at present, short sellers hold a 0.01% of that float. On March 28, 2024, the average trading volume of CHRO was 35.87K shares.
CHRO) stock’s latest price update
The stock price of Chromocell Therapeutics Corp. (AMEX: CHRO) has jumped by 11.07 compared to previous close of 2.44. Despite this, the company has seen a fall of -5.24% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-11 that AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) — Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CHRO’s Market Performance
The volatility ratio for the week is 13.79%, and the volatility levels for the past 30 days are at 11.12% for CHRO. The simple moving average for the past 20 days is -15.96% for CHRO’s stock, with a -23.94% simple moving average for the past 200 days.
CHRO Trading at -23.94% from the 50-Day Moving Average
After a stumble in the market that brought CHRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.83% of loss for the given period.
Volatility was left at 11.12%, however, over the last 30 days, the volatility rate increased by 13.79%, as shares sank -27.73% for the moving average over the last 20 days.
During the last 5 trading sessions, CHRO fell by -5.24%, in comparison to the 20-day moving average, which settled at $3.17. In addition, Chromocell Therapeutics Corp. saw -43.54% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRO
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.00.
Conclusion
To sum up, Chromocell Therapeutics Corp. (CHRO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
